Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 5/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 3/20 | 0.45 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | HPD | P32754 | 1/20 | 0.43 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL955931 | 0.91 | HPGD (0.46) | NR4A2HPGDPTPN1MAOBFFAR4 | |
| SCHEMBL15300294 | 0.87 | HPD (0.58) | NR4A2PTPN1ALKBH1MAOBHPD | |
| SCHEMBL958298 | 0.86 | NR4A2 (0.49) | NR4A2HPGDALKBH1MAOBALDH1A1 | |
| SCHEMBL1760752 | 0.85 | HPGD (0.48) | NR4A2HPGDPTPN1MAOBALDH1A1 | |
| SCHEMBL237393 | 0.84 | HPGD (0.50) | NR4A2HPGDPTPN1MAOBALDH1A1 | |
| SCHEMBL960147 | 0.84 | NR4A2 (0.54) | NR4A2HPGDPTPN1MAOB | |
| SCHEMBL2087710 | 0.84 | MAOB (0.43) | NR4A2HPGDPTPN1MAOB | |
| Potassium SCHEMBL2089657 | 0.83 | HPGD (0.49) | NR4A2HPGDPTPN1MAOBALDH1A1 | |
| SCHEMBL2088037 | 0.83 | HPGD (0.49) | NR4A2HPGDPTPN1MAOBALDH1A1 | |
| SCHEMBL2089649 | 0.83 | HPGD (0.49) | NR4A2HPGDPTPN1MAOBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 112 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | claimed |
| US-9115072-B2 | Compounds and method for reducing uric acid | WELLSTAT THERAPEUTICS CORPORATION (US) | 2015-08-25 | — | — | US | claimed |
| CN-101969773-B | compounds and methods for reducing uric acid | WELLSTAT THERAPEUTICS CORP. (US) | 2015-08-19 | — | — | CN | claimed |
| EP-1461323-B1 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORP (US) | 2013-10-09 | — | — | EP | claimed |
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2013-10-03 | — | — | US | claimed |
| US-8487000-B2 | 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis | Wellstat Therapertics Corporation (US) | 2013-07-16 | — | — | US | claimed |
| JP-4711621-B2 | — | — | 2011-06-29 | — | — | JP | claimed |
| CN-101969773-A | compounds and methods for reducing uric acid | WELLSTAT THERAPEUTICS CORP | 2011-02-09 | — | — | CN | claimed |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2011-01-20 | — | — | US | claimed |
| EP-2268141-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2011-01-05 | — | — | EP | claimed |
| WO-2009151695-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | WELLSTAT THERAPEUTICS CORPORATION (US) | 2009-12-17 | — | — | WO | claimed |
| CN-100344616-C | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORP (US) | 2007-10-24 | — | — | CN | claimed |
| US-20050090555-A1 | Compound for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2005-04-28 | — | — | US | claimed |
| CN-1608055-A | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORP (US) | 2005-04-20 | — | — | CN | claimed |
| US-20040242692-A1 | Compounds for the treatment of metabolic disorders | WELLSTAT THERAPEUTICS CORPORATION | 2004-12-02 | — | — | US | claimed |
| EP-1461323-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Wellstat Therapeutics Corporation (US) | 2004-09-29 | — | — | EP | claimed |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | PHARMA CINQ, LLC | 2003-08-07 | — | — | US | claimed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | claimed |
| EP-3517109-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | Wellstat Therapeutics Corporation (US) | 2019-07-31 | — | — | EP | disclosed |
| WO-2002100341-A2 | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | WELLSTAT THERAPEUTICS CORPORATION (US) | 2002-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130259850-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | RCC2, HAX1, SLC10A6 | NR4A2 1494/4885HPGD 3648/4885PTPN1 2554/4885 |
| US-20050090555-A1 | Compound for the treatment of metabolic disorders | GOT2, OAT, GPR119 | NR4A2 2462/4885HPGD 379/4885PTPN1 4413/4885 |
| US-20040242692-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | NR4A2 2849/4885HPGD 381/4885PTPN1 4514/4885 |
| US-20110014176-A1 | COMPOUNDS AND METHOD FOR REDUCING URIC ACID | UGP2, TAS2R46, PYCARD | NR4A2 1952/4885HPGD 1998/4885PTPN1 4020/4885 |
| US-20030149107-A1 | Compounds for the treatment of metabolic disorders | GOT2, OAT, CPT1B | NR4A2 2849/4885HPGD 381/4885PTPN1 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.